Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene

Journal of Clinical Oncology

Volumn 31, Issue 5, 2013, Pages 523-529

  Taneja, Samir S ^a   Morton, Ronald ^b   Barnette, Gary ^b   Sieber, Paul ^c   Hancock, Michael L ^b   Steiner, Mitchell ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b GTx   (United States)

^c Urological Associates of Lancaster   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOREMIFENE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CANCER DIAGNOSIS; CANCER FATIGUE; CANCER SURVIVAL; CATARACT; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GASTROESOPHAGEAL REFLUX; HEMATURIA; HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA; HUMAN; HYPERTENSION; INSOMNIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PANCREAS ADENOMA; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINE RETENTION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TOREMIFENE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84875369106     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.7634     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. Lieberman R: Chemoprevention of prostate cancer: Current status and future directions. Cancer Metastasis Rev 21:297-309, 2002 (Pubitemid 36071917)
3. Brewster AM, Patterson SL, Forman MR, et al: Conference report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res 3:1044-1048, 2010
4. Lippman SM, Lee JJ: Reducing the "risk" of chemoprevention: Defining and targeting high risk - 2005 AACR Cancer Res and Prevention Foundation Award Lecture. Cancer Res 66:2893-2903, 2006
5. Schlesinger C, Bostwick DG, Iczkowski KA: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: Predictive value for cancer in current practice. Am J Surg Pathol 29:1201-1207, 2005 (Pubitemid 41232993)
6. McNeal JE, Bostwick DG: Intraductal dysplasia: A premalignant lesion of the prostate. Hum Pathol 17:64-71, 1986 (Pubitemid 16163546)
7. Bostwick DG, Qian J: High-grade prostatic intraepithelial neoplasia. Mod Pathol 17:360-379, 2004 (Pubitemid 41646613)
8. Lefkowitz GK, Sidhu GS, Torre P, et al: Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? Urology 58:999-1003, 2001 (Pubitemid 34017288)
9. Weinstein MH, Epstein JI: Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol 24:624-629, 1993 (Pubitemid 23162230)
10. Herawi M, Kahane H, Cavallo C, et al: Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled. J Urol 175:121-124, 2006 (Pubitemid 41797107)
11. Kronz JD, Allan CH, Shaikh AA, et al: Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: Data on men with more than one follow-up biopsy. Am J Surg Pathol 25:1079-1085, 2001 (Pubitemid 32685907)
12. Lefkowitz GK, Taneja SS, Brown J, et al: Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 168:1415-1418, 2002 (Pubitemid 35034136)
13. Lee MC, Moussa AS, Yu C, et al: Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer. J Urol 184: 1958-1962, 2010
14. Abdel-Khalek M, El-Baz M, Ibrahiem el-H: Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: A multivariate analysis model. BJU Int 94: 528-533, 2004 (Pubitemid 39256474)
15. Risbridger GP, Bianco JJ, Ellem SJ, et al: Oestrogens and prostate cancer. Endocr Relat Cancer 10:187-191, 2003 (Pubitemid 36758648)
16. Ho SM: Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 91:491-503, 2004
17. Leav I, Lau KM, Adams JY, et al: Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159:79-92, 2001 (Pubitemid 33704195)
18. Taneja SS, Smith MR, Dalton JT, et al: Toremifene: A promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs 15:293-305, 2006 (Pubitemid 43338149)
19. Steiner MS, Raghow S: Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J Urol 21:31-36, 2003 (Pubitemid 44175294)
20. Price D, Stein B, Sieber P, et al: Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: Results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 176:965-970, 2006
21. Epstein JI, Herawi M: Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: Implications for patient care. J Urol 175:820-834, 2006 (Pubitemid 43199991)
22. Netto GJ, Epstein JI: Widespread high-grade prostatic intraepithelial neoplasia on prostatic needle biopsy: A significant likelihood of subsequently diagnosed adenocarcinoma. Am J Surg Pathol 30:1184- 1188, 2006 (Pubitemid 44299352)
23. Godoy G, Huang GJ, Patel T, et al: Long-term follow-up of men with isolated high-grade prostatic intra-epithelial neoplasia followed by serial delayed interval biopsy. Urology 77:669-674, 2011
24. Roscigno M, Scattoni V, Freschi M, et al: Monofocal and plurifocal high-grade prostatic intraepithelial neoplasia on extended prostate biopsies: Factors predicting cancer detection on extended repeat biopsy. Urology 63:1105-1110, 2004 (Pubitemid 38746813)
25. Akhavan A, Keith JD, Bastacky SI, et al: The proportion of cores with high-grade prostatic intraepithelial neoplasia on extended-pattern needle biopsy is significantly associated with prostate cancer on site-directed repeat biopsy. BJU Int 99:765-769, 2007 (Pubitemid 46439563)
26. Roobol MJ, van der Cruijsen IW, Schröder FH: No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam). Urology 63:892-897, 2004 (Pubitemid 38596673)
27. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224, 2003 (Pubitemid 36859473)
28. Andriole GL, Bostwick DG, Brawley OW, et al: Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192-1202, 2010